Platelet Rich Plasma as a Potential Therapy for Chronic Toxoplasmosis in Immunocompetent and Immunocompromised Murine Model
Pharmaceuticals · 08.06.2026 · 19 (6) · 908
DOI: 10.3390/ph19060908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.06.2026. Verfasst von Majed H Wakid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research (DSR) at King Abdulaziz University.
Abstract (Originalsprache)
Background
Toxoplasma gondii (T. gondii) is one of the most prevalent parasitic zoonoses worldwide, and the host’s immunological state significantly influences its clinical manifestations, which can be potentially fatal in immunocompromised hosts. The unavailability of a vaccine, combined with the considerable toxicity of existing medications, necessitates the urgent search for new therapies or adjunctive techniques, including regenerative and immunomodulatory approaches. Hence, the present study investigated, for the first time, the therapeutic potential of syngeneic platelet rich plasma (PRP) against T. gondii ME49 strain-induced chronic toxoplasmosis in both immunocompetent and immunosuppressed mouse models.
Methods
72 albino mice were divided into two sections, immunocompetent and immunosuppressed. Each section contained six groups: healthy, model, cotrimoxazole (CTZ)-treated, PRP-treated, half-dose of both CTZ and PRP-treated, and full-dose of both CTZ and PRP-treated. Treatment efficacy was assessed via parasitological, histological, immunohistochemical, and immunological analyses.
Results
PRP, especially when coadministered with the CTZ, mitigated the consequences of toxoplasmosis by significantly reducing brain cyst counts (p < 0.0001), restoring brain tissue architecture, modulating apoptotic pathways by restoring caspase-3 expression in the brain, and normalizing systemic IFN-γ, TNF-α, and IL-10 cytokine profiles.
Conclusions
The findings highlight PRP as an adjunct to the reference treatment, CTZ, for controlling toxoplasmosis in both immunocompetent and immunosuppressed conditions via anti-infective, neuroprotective, and immunomodulatory activities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 22254, Saudi Arabia.
- Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 22254, Saudi Arabia.
- Department of Parasitology, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, Giza 12411, Egypt.
- Department of Pathology, Theodor Bilharz Research Institute, Kornaish El-Nile St., Giza 12411, Egypt.
- Department of Biological Sciences, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia.
ORCID-Profile: Majed H Wakid, Olfat A Hammam, Muslimah N Alsulami, Eman S El-Wakil
Förderung
- Deanship of Scientific Research (DSR) at King Abdulaziz University
Zitieren
APA
Wakid, M. H., Zalat, R. S., Hammam, O. A., Alsulami, M. N., & El-Wakil, E. S. (2026). Platelet Rich Plasma as a Potential Therapy for Chronic Toxoplasmosis in Immunocompetent and Immunocompromised Murine Model. Pharmaceuticals, 19(6), 908. https://doi.org/10.3390/ph19060908
Vancouver
Wakid MH, Zalat RS, Hammam OA, Alsulami MN, El-Wakil ES. Platelet Rich Plasma as a Potential Therapy for Chronic Toxoplasmosis in Immunocompetent and Immunocompromised Murine Model. Pharmaceuticals. 2026;19(6):908. doi:10.3390/ph19060908
BibTeX
@article{Wakid2026,
author = {Wakid, Majed H and Zalat, Rabab S and Hammam, Olfat A and Alsulami, Muslimah N and El-Wakil, Eman S},
title = {Platelet Rich Plasma as a Potential Therapy for Chronic Toxoplasmosis in Immunocompetent and Immunocompromised Murine Model},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {908},
doi = {10.3390/ph19060908}
}
EUVIMED